By 2019, DNDi aims to deliver from its paediatric HIV portfolio:

  • Two new four-in-one paediatric formulations containing a PI (LPV/r) and two NRTIs (ABC or AZT and 3TC)
  • One stand-alone paediatric booster RTV for HIV-TB co-infected children

 

The current paediatric HIV portfolio includes:

Translation

Translation

Two ‘4-in-1’ LPV/r/ABC/3TC

Development

Development

LPV/r pellets with dual NRTI FDC

Implementation

Implementation

Superbooster therapy paediatric HIV/TB

 

For more details on each project, see DNDi‘s Global Portfolio